Zevalin Medicare Reimbursement: Idec Predicts Smooth Transition Into 2003
Executive Summary
Idec hopes to ensure a "seamless transition" in pass-through payments for Zevalin should the Centers for Medicare & Medicaid Services change coverage rates for 2003
You may also be interested in...
Aranesp, Procrit Are “Functionally Equivalent,” CMS Says In Final OPPS Rule
The National Cancer Institute will conduct a head-to-head study of Amgen's Aranesp (darbepoetin) and Ortho's Procrit (epoetin) in order to define equivalent doses of the anemia agents, CMS reports in the final Hospital Outpatient Prospective Payment System rule for 2003
Idec Zevalin NHL Indication Split By Accelerated/Standard Approval
Idec/Genentech will conduct a postmarketing study of Zevalin in non-Hodgkin's lymphoma patients who have not failed Rituxan therapy to fulfill accelerated approval requirements
BIO Proposes Increased Base Rates For Drugs In 2002 Medicare OPPS
The Centers for Medicare & Medicaid Services should raise the base rates for drugs in the Medicare hospital outpatient prospective payment system to offset a 68.9% pro-rata reduction in "pass-through" payments, the Biotechnology Industry Organization contends